Over 20 years ago biologics were introduced for psoriasis and PsA. Since then even more targeted treatments have been introduced. Listen as dermatologist Dr. Steven Feldman from Wake Forest University School of Medicine, shares his perspectives on the latest treatments, resident memory T-cells, and what's to come (such as an oral IL-23 agent) with moderator Max Blitstein. This episode is provided with support from Bristol Myers Squibb.